GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B7136 FananserinSummary: 5-HT2A receptor antagonist -
C5675 Fendiline (hydrochloride)Summary: α2-adrenergic receptor antagonist -
B7117 TCB-2Summary: 5-HT2A receptor agonist -
C5580 RaceanisodamineSummary: weak antagonist of α1-adrenoceptors -
B7094 LP 44Summary: 5-HT7 receptor agonist -
C5286 (R,S)-AtenololSummary: β1-adrenergic receptor antagonist -
B7032 EMD 386088 hydrochlorideSummary: 5-HT6 receptor agonist -
C5043 Bufuralol (hydrochloride)Summary: non-specific β-adrenergic blocker -
B6973 PNU 22394 hydrochlorideSummary: 5-HT2C agonist and partial 5-HT2A/5-HT2B agonist -
C4521 Celiprolol (hydrochloride)Summary: β1 adrenergic receptor antagonist and β2 adrenergic receptor partial agonist
